Pharmaceuticals

Esketamine Market Forecast 2026–2035: Data Trends and Industry Insights

March 2, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the esketamine market from 2026–2035 with trusted insights from The Business Research Company

What is the expected shift in the Esketamine Market’s size between 2026 and 2030?

The esketamine market’s valuation has experienced substantial growth in recent years. It is projected to increase from $1.51 billion in 2025 to $1.67 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 10.8%. The expansion observed in the historic period is primarily due to unmet needs in major depressive disorder, the limitations of traditional antidepressants, regulatory approvals for nasal esketamine, growing mental health awareness, and the proliferation of specialty psychiatric clinics.

The esketamine market is anticipated to experience substantial growth in the upcoming years, with projections indicating it will reach $2.5 billion by 2030, driven by a compound annual growth rate (CAGR) of 10.6%. This expansion throughout the forecast period can be attributed to the increasing prevalence of treatment-resistant depression, a rising demand for fast-acting therapies, the wider availability of supervised outpatient administration, the development of mental health infrastructure, and continuous investment in clinical research. Major trends expected during this period encompass the growing acceptance for treatment-resistant depression, the expansion of nasal spray administration methods, increased utilization in acute psychiatric care settings, enhanced monitoring and controlled distribution practices, and ongoing research into rapid-acting antidepressants.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=23393&type=smp

Which Drivers Are Shaping Strategic Decisions In The Esketamine Market?

The increasing prevalence of treatment-resistant depression (TRD) is anticipated to propel the growth of the esketamine market in the coming years. Treatment-resistant depression (TRD) is defined as depression that does not improve after attempting at least two different antidepressant medications at proper doses for a sufficient duration. The rise in treatment-resistant depression (TRD) is attributed to the limited efficacy of conventional antidepressants, which results in prolonged and recurrent depressive episodes. Esketamine helps treatment-resistant depression (TRD) by providing a fast-acting mechanism that targets the NMDA receptors, offering relief for patients who do not respond to traditional antidepressants. For instance, in September 2023, the National Institute of Mental Health (NIMH), a US-based federal agency, reported that, in 2023, about 30% of individuals with major depressive disorder in the U.S. are resistant to standard treatments. Therefore, the rising incidence of treatment-resistant depression is driving the growth of the esketamine market.

What Segment Classifications Make Up The Esketamine Market?

The esketamine market covered in this report is segmented –

1) By Formulation Type: Nasal Spray, Injectable Form

2) By Indication: Treatment-Resistant Depression (TRD), Major Depressive Disorder with Suicidal Ideation or Behavior

3) By Patient Type: Adult Patients

4) By Treatment Setting: Hospital-Based Administration, Certified Specialty Clinics

5) By Distribution Channel: Hospital Pharmacies, Specialty Pharmacies

Subsegments:

1) By Nasal Spray: Single-Agent Esketamine Nasal Spray, Esketamine + Oral Antidepressant Combination Therapy

2) By Injectable Form: Intravenous (IV) Esketamine, Intramuscular (IM) Esketamine

Which Trends Are Guiding The Evolution Of The Esketamine Market?

Leading companies in the esketamine market are focusing on developing advanced therapeutic solutions, such as monotherapy, to enhance relief from depressive symptoms beyond what a placebo offers. Monotherapy refers to using a single drug or treatment to manage a disease or medical condition, rather than combining multiple therapies. For instance, in January 2025, Johnson & Johnson, a US-based pharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) had approved SPRAVATO (esketamine) as the first and only monotherapy for adults with treatment-resistant depression (TRD). Supported by clinical trials, this approval demonstrated that SPRAVATO could rapidly alleviate depressive symptoms, with significant improvements observed within 24 hours. This breakthrough provides a critical option for approximately 30% of individuals who do not respond to traditional antidepressants, eliminating the need for concurrent oral medications. While SPRAVATO has a favorable safety profile, it is administered under a Risk Evaluation and Mitigation Strategy (REMS) to address potential side effects. This milestone marks a significant advancement in TRD treatment, offering renewed hope for improved patient outcomes.

Which Leading Companies Dominate The Esketamine Market Share?

Major companies operating in the esketamine market are Johnson & Johnson, Janssen Pharmaceuticals, Sage Therapeutics Inc., VistaGen Therapeutics Inc., Cerecor Inc., Celon Pharma S.A., Hikma Pharmaceuticals plc, Seqens Group, Arevipharma GmbH, Nortec Química S.A., Supriya Lifescience Ltd., Maithri Drugs Pvt. Ltd., SynZeal Research Pvt. Ltd., XWPharma Ltd., Sun Pharmaceutical Industries Ltd., Dr. Reddy’s Laboratories Ltd., Lupin Limited, Aurobindo Pharma Ltd., H. Lundbeck A/S, Otsuka Pharmaceutical Co. Ltd.

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/esketamine-global-market-report

How Does The Esketamine Market Perform Across Major Global Regions?

North America was the largest region in the esketamine market in 2025. The regions covered in the esketamine market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Esketamine Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=23393&type=smp

Browse Through More Reports Similar to the Global Esketamine Market 2026, By The Business Research Company

Epinephrine Market Report 2026

https://www.thebusinessresearchcompany.com/report/epinephrine-global-market-report

Anti Infective Drugs Market 2026

https://www.thebusinessresearchcompany.com/report/anti-infective-drugs-market

Anticholinergic Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/anticholinergic-drugs-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795